Lupin launches Mirabegron Extended-Release Tablets in US Ruchika Sharma4 Sept 2024 8:30 PM ISTMumbai: Global pharma major Lupin Limited has announced the launch of Mirabegron Extended-Release Tablets, 50 mg, in the United States, after having...
Zydus Lifesciences launches Mirabegron ER Tablets in US for overactive bladder treatment Ruchika Sharma22 April 2024 2:47 PM ISTMirabegron is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency.
Lupin unveils Mirabegron ER tablets in US Ruchika Sharma22 April 2024 12:09 PM ISTMumbai: Global pharma major Lupin Limited has announced the launch of Mirabegron Extended-Release Tablets, 25 mg, in the United States, after...
Justify bioequivalent data: CDSCO Panel Tells Sun Pharma on Mirabegron Extended-release Tablets Dr. Divya Colin8 March 2024 6:00 PM ISTNew Delhi: After reviewing the bioequivalence (BE) report of Mirabegron extended-release Tablets 50 mg presented by drug major Sun Pharma, the Subject...
Zydus Lifesciences US arm bags USFDA nod for generic version of Mirabegron ER tablets Ruchika Sharma3 Oct 2022 12:15 PM ISTMirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and urinary frequency.
Lupin bags USFDA approval for Mirabegron ER tablets to treat overactive bladder Ruchika Sharma30 Sept 2022 11:28 AM ISTThe product will be manufactured at Lupin's facility in Nagpur, India.
